Skip to main content
NVDA+0.25%AAPL+0.04%GOOGL-0.61%MSFT+0.10%AMZN+0.08%TSM+0.96%SPCX+5.15%META+0.16%AVGO+0.07%TSLA+0.06%SKHY+0.02%BRK-B+0.59%LLY+0.18%MU+0.40%JPM-1.01%WMT-0.55%AMD+1.65%V-1.25%XOM-3.54%JNJ+0.03%ASMLa+1.26%INTC+4.03%0700.HK-1.23%MA-0.96%ABBV-0.17%1398.HK+0.67%CSCO-2.12%CVX-2.86%BAC-2.72%ORCL+2.00%COST-0.84%KO-0.95%DELL+3.64%CAT-0.10%0005.HK+0.81%PG+0.24%HSBA.L+0.27%UNH-0.18%LRCX-0.61%AP2d+0.95%AMAT-1.37%GE+1.91%MS-1.83%3988.HK+0.34%1816.HK-0.69%NFLX-1.91%0857.HK-1.90%HD-0.99%PM-1.24%0939.HK+0.31%USDJPY+1.73%NZDUSD-1.71%EURUSD-1.19%AUDUSD-1.16%USDCHF+1.14%GBPUSD-1.06%USDTHB+0.97%CADJPY+0.89%NZDCAD-0.87%USDCAD+0.85%CHFJPY+0.71%GBPJPY+0.62%GBPNZD+0.62%NZDCHF-0.60%AUDJPY+0.57%AUDNZD+0.55%EURNZD+0.55%EURJPY+0.51%GBPTRY+0.41%EURCAD-0.37%GBPHKD+0.32%USDTRY+0.30%AUDCAD-0.30%GBPMXN-0.28%CADCHF+0.28%GBPCAD-0.22%USDILS+0.16%EURGBP-0.09%GBPAUD+0.07%EURCHF-0.07%USDCNH+0.06%USDCOP-0.04%GBPCHF+0.03%USDHKD+0.02%AUDCHF-0.02%EURAUD-0.02%NZDJPY+0.01%AUDSGD0.00%SGDJPY0.00%CHFSGD0.00%NOKJPY0.00%EURCZK0.00%NZDSGD0.00%EURNOK0.00%NZDMXN0.00%USDMXN0.00%USDNOK0.00%PLNJPY0.00%USDZAR0.00%EURPLN0.00%CHFNOK0.00%USDPLN0.00%USDSEK0.00%USDDKK0.00%EURSEK0.00%EURHKD0.00%GBPZAR0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%GBPSGD0.00%USDSGD0.00%EURDKK0.00%GAGUSD0.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%W10.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.59%ETHUSD+0.37%USDTUSD+0.01%XRPUSD+0.70%SOLUSD+1.59%TRXUSDT+1.00%ZECUSDT+18.53%DOGEUSD+0.70%XMRUSDT-2.80%LINKUSD+0.44%XLMUSD+2.90%BCHUSDT+0.82%UNIUSD+1.64%LTCUSD-0.03%TONUSD+29.54%HBARUSDT-1.31%SUIUSD+2.98%TAOUSDT+0.96%AAVEUSD-2.32%DOTUSDT+6.77%ICPUSDT+1.36%ONDOUSDT+3.50%WLDUSDT+2.11%ARBUSDT+9.35%ATOMUSDT-1.28%JUPUSDT+0.20%INJUSDT-1.00%STXUSDT+1.15%FETUSDT+2.51%PYTHUSDT-0.94%TIAUSDT+2.70%SEIUSDT+1.07%IMXUSDT-1.25%GRTUSDT+1.83%OPUSDT-0.14%WIFUSDT+1.97%POLUSDT+0.69%IOTAUSDT-0.24%AXSUSDT+0.14%FARTCOINUSDT-0.22%EOSUSDT-0.44%DYDXUSDT+0.22%ORDIUSDT+2.81%GALAUSDT-2.15%NOTUSDT+2.56%RONINUSDT-2.40%NVDA+0.25%AAPL+0.04%GOOGL-0.61%MSFT+0.10%AMZN+0.08%TSM+0.96%SPCX+5.15%META+0.16%AVGO+0.07%TSLA+0.06%SKHY+0.02%BRK-B+0.59%LLY+0.18%MU+0.40%JPM-1.01%WMT-0.55%AMD+1.65%V-1.25%XOM-3.54%JNJ+0.03%ASMLa+1.26%INTC+4.03%0700.HK-1.23%MA-0.96%ABBV-0.17%1398.HK+0.67%CSCO-2.12%CVX-2.86%BAC-2.72%ORCL+2.00%COST-0.84%KO-0.95%DELL+3.64%CAT-0.10%0005.HK+0.81%PG+0.24%HSBA.L+0.27%UNH-0.18%LRCX-0.61%AP2d+0.95%AMAT-1.37%GE+1.91%MS-1.83%3988.HK+0.34%1816.HK-0.69%NFLX-1.91%0857.HK-1.90%HD-0.99%PM-1.24%0939.HK+0.31%USDJPY+1.73%NZDUSD-1.71%EURUSD-1.19%AUDUSD-1.16%USDCHF+1.14%GBPUSD-1.06%USDTHB+0.97%CADJPY+0.89%NZDCAD-0.87%USDCAD+0.85%CHFJPY+0.71%GBPJPY+0.62%GBPNZD+0.62%NZDCHF-0.60%AUDJPY+0.57%AUDNZD+0.55%EURNZD+0.55%EURJPY+0.51%GBPTRY+0.41%EURCAD-0.37%GBPHKD+0.32%USDTRY+0.30%AUDCAD-0.30%GBPMXN-0.28%CADCHF+0.28%GBPCAD-0.22%USDILS+0.16%EURGBP-0.09%GBPAUD+0.07%EURCHF-0.07%USDCNH+0.06%USDCOP-0.04%GBPCHF+0.03%USDHKD+0.02%AUDCHF-0.02%EURAUD-0.02%NZDJPY+0.01%AUDSGD0.00%SGDJPY0.00%CHFSGD0.00%NOKJPY0.00%EURCZK0.00%NZDSGD0.00%EURNOK0.00%NZDMXN0.00%USDMXN0.00%USDNOK0.00%PLNJPY0.00%USDZAR0.00%EURPLN0.00%CHFNOK0.00%USDPLN0.00%USDSEK0.00%USDDKK0.00%EURSEK0.00%EURHKD0.00%GBPZAR0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%EURSGD0.00%AUDDKK0.00%CHFSEK0.00%GBPSGD0.00%USDSGD0.00%EURDKK0.00%GAGUSD0.00%XAGUSD0.00%HG10.00%S10.00%C10.00%XNGUSD0.00%USOIL0.00%W10.00%XAUUSD0.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.59%ETHUSD+0.37%USDTUSD+0.01%XRPUSD+0.70%SOLUSD+1.59%TRXUSDT+1.00%ZECUSDT+18.53%DOGEUSD+0.70%XMRUSDT-2.80%LINKUSD+0.44%XLMUSD+2.90%BCHUSDT+0.82%UNIUSD+1.64%LTCUSD-0.03%TONUSD+29.54%HBARUSDT-1.31%SUIUSD+2.98%TAOUSDT+0.96%AAVEUSD-2.32%DOTUSDT+6.77%ICPUSDT+1.36%ONDOUSDT+3.50%WLDUSDT+2.11%ARBUSDT+9.35%ATOMUSDT-1.28%JUPUSDT+0.20%INJUSDT-1.00%STXUSDT+1.15%FETUSDT+2.51%PYTHUSDT-0.94%TIAUSDT+2.70%SEIUSDT+1.07%IMXUSDT-1.25%GRTUSDT+1.83%OPUSDT-0.14%WIFUSDT+1.97%POLUSDT+0.69%IOTAUSDT-0.24%AXSUSDT+0.14%FARTCOINUSDT-0.22%EOSUSDT-0.44%DYDXUSDT+0.22%ORDIUSDT+2.81%GALAUSDT-2.15%NOTUSDT+2.56%RONINUSDT-2.40%
AB

Arbutus Biopharma Corp (ABUS)

NASDAQ • Healthcare

$5.05
-$0 (-0.2%)
Market closed

Last close at September 16, 2026 at 20:00 UTC

Open$5.06
Day Range$5.02 - $5.09
Avg. Volume (3M)5.1M
Market Cap$999.8M
P/E Ratio6.4
52 Week Range
$3.5$5.45
Next EarningsIn 61 daysNov 16, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$1M100%
Gross Profitminus cost of goods$1M100%

Fundamentals & Financials

Revenue (TTM)
$181.7M
Net Income (TTM)
$153M
EPS (TTM)
$0.79
ROA (TTM)
55.85%
Current Ratio
81.42
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+71.5%Q1 2026-$0.01
+3000.0%Q2 2026$0.87
-50.0%Q3 2026-$0.03
Next

Nov 16

in 61 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Arbutus Biopharma Corp

Arbutus Biopharma Corp is a NASDAQ-listed biotechnology company that develops novel therapeutics for infectious disease, with its work centered on chronic hepatitis B. In FY2025, the company recorded $14.1 million in revenue. Its programs and supporting technology are based in the United States from Warminster, Pennsylvania.

Name
Arbutus Biopharma Corp
CEO
Lindsay Androski
Website
www.arbutusbio.com
Industry
Healthcare
Year Founded
2005
Employees
19

Today's Snapshot

AI-generated

ABUS ended the day slightly lower at 5.05, in line with a flat sector.

Trading Volume

Above 10d avg 3.8M

3.9M

vs S&P 500 Today

Moderate Outperformance

+0.38%

Updated: September 16, 2026 at 20:02 UTC

ABUS Headlines

Arbutus plans US$230m share tender offer

August 21, 2026

3 min read
View All News

Technical Indicators

4 Buy3 Neutral1 Sell
ABUS presents a constructive technical profile with a favored bias to the upside supported by a positive medium-to-long moving average structure and a trend-strength reading that favors buyers. Momentum is neutral overall with RSI and MACD near hold, while shorter-term averages slightly lag the current price; volatility is modest and does not undermine the gradual uptrend. On-balance volume is mixed, tempering conviction, and the pivot sits near the market. Taken together these indicators favor a bullish tilt. Technical takeaway: Buy.
All signals
  • EMA (5 indicators)$4.59 - $5.10
    Buy
  • RSI (14)53.57
    Neutral
  • Stochastic %K (14, 3, 3)33.95
    Neutral
  • MACD Level (12, 26)0.09
    Neutral

Peers & Related Assets

TNGXTango Therapeutics, Inc.
$23.35-2.3%
SEPNSepterna Inc
$38.44-1.1%
BCAXBicara Therapeutics Inc. Common Stock
$22-3.0%
SVRASavara Inc.
$5.13-2.5%
KURAKura Oncology, Inc.
$11.2-0.9%
SPRYARS Pharmaceuticals, Inc.
$4.17-2.0%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.